Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma
2021 · Cancer Cell · 583 citations
https://doi.org/10.1016/j.ccell.2021.02.015
D
David A. Braun
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
453
Papers
7.4K
Citations
36
h-index
71
i10-index
David A. Braun is an academic researcher from Yale New Haven Hospital. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Renal cell carcinoma treatment & Cancer Genomics and Diagnostics. The author has an h-index of 36, co-authored 386 publications.
ORCID: 0000-0003-4543-5553Papers by this author
worksProgressive immune dysfunction with advancing disease stage in renal cell carcinoma
2021 · Cancer Cell · 483 citations
https://doi.org/10.1016/j.ccell.2021.02.013
Metabolomic adaptations and correlates of survival to immune checkpoint blockade
2019 · Nature Communications · 218 citations
https://doi.org/10.1038/s41467-019-12361-9
Landscape of helper and regulatory antitumour CD4+ T cells in melanoma
2022 · Nature · 178 citations
https://doi.org/10.1038/s41586-022-04682-5
Cytokine Response Is Determined by Duration of Receptor and Signal Transducers and Activators of Transcription 3 (STAT3) Activation
2012 · Journal of Biological Chemistry · 163 citations
https://doi.org/10.1074/jbc.m112.386573
A neoantigen vaccine generates antitumour immunity in renal cell carcinoma
2025 · Nature · 129 citations
https://doi.org/10.1038/s41586-024-08507-5
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat